The shares offered to the public are being offered pursuant to an existing effective shelf registration statement (including a base prospectus) that has been filed by Regeneron with the U.S. Securities and Exchange Commission (the "SEC"). This includes the previously announced overallotment option that has been fully exercised by underwriters. PARIS - May 25, 2020 – Sanofi today announced its intent to sell its equity investment in Regeneron (NASDAQ: REGN) through a registered public offering and related share repurchase by Regeneron. The registered offering and share repurchase will have no impact on the ongoing collaboration between Sanofi and Regeneron. If the option is fully exercised, the offering and repurchase will together result in gross proceeds to Sanofi of $11.7 billion and the sale of Sanofi’s entire holding in Regeneron, excluding 400,000 Regeneron shares that Sanofi is retaining. Sanofi announces pricing of Regeneron stock offering. The transaction has been approved by Sanofi and Regeneron’s Boards of Directors. Sanofi raised its 2020 earnings forecast on Wednesday after its second-quarter results were boosted by cost cuts and the sale of most of its 20.6% stake in U.S. company Regeneron , although revenue was hit by the coronavirus crisis. This includes the previously announced overallotment option that has been fully exercised by underwriters. PARIS – May 26, 2020 – Sanofi today announced that it has agreed to sell 11.8 million shares of Regeneron, Inc. (NASDAQ: REGN) common stock through a registered offering at a price of $515.00 per share. Sanofi announces closing of Regeneron stock sale. Sanofi announces closing of Regeneron stock sale PARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron … The registered offering and share repurchase will have no impact on the ongoing collaboration between Sanofi and Regeneron. The longtime partnership between Regeneron and Sanofi continues to yield fruit. Sanofi announces closing of Regeneron stock sale. In addition, the companies are also conducting a second trial in countries outside of the U.S. Sanofi announces closing of Regeneron stock sale PARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million... 21/06/2020 12:20:49 Cookie Policy +44 (0) 203 8794 460 Free Membership Login. Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration. French drugmaker Sanofi has sold half of its stake in Regeneron, the US pharmaceutical group, in a $6.1bn deal that marks the biggest healthcare equity offering on record. Sanofi holds a 20.6% stake in Regeneron, and has said it will shed around 12.8 million shares out of its current 23.2 million stake. “The decision to divest our holdings is consistent with our efforts to enhance value creation for our shareholders. Before you invest, you should read the prospectus in that registration statement and other documents Regeneron has filed with the SEC, including the preliminary prospectus supplement dated May 26, 2020, for more complete information about Regeneron and this offering. Regeneron Pharmaceuticals, Inc. and its affiliates, Regeneron Ireland Unlimited Company and Regeneron UK Limited (together, "Regeneron", "we", "us" or "our") use this data to make the Sites more user-friendly and efficient. Fitch Affirms Sanofi at 'A+'/Stable Following Regeneron Sale Fitch Ratings - Frankfurt am Main - 03 Jun 2020: Fitch Ratings has affirmed Sanofi SA's Long-Term Issuer Default Rating (IDR) and its senior unsecured debt rating at 'A+'. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed by Regeneron with the SEC and will be available on the SEC website at www.sec.gov. This includes the previously announced overallotment option that has been fully […] PARIS – May 26, 2020 – Sanofi today announced that it has agreed to sell 11.8 million shares of Regeneron, Inc. (NASDAQ: REGN) common stock through a registered offering at a price of $515.00 per share. Sanofi originally purchased a shareholding in Regeneron in 2004. PARIS – May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron (NASDAQ: REGN) common stock through a registered offering at a public offering price of $515.00 per share. Sanofi announces closing of Regeneron stock sale. The share sale was set to begin Tuesday as part of a registered direct offering. Sanofi announces closing of Regeneron stock sale. Click here for more information on cookies, Sanofi announces sale of 21.6 million shares held in Regeneron, Gross proceeds of $11.1 billion to Sanofi to further Company’s ability to execute innovation and growth strategy. Regeneron has agreed to repurchase $5 billion of its stock from Sanofi conditional on completion of the proposed public offering. Sanofi announces closing of Regeneron stock sale Fitch has also affirmed Sanofi's … PARIS - May 25, 2020 –Sanofi today announced its intent to sell its equity investment in Regeneron (NASDAQ: REGN) through a registered public offering and related share repurchase by Regeneron. News Feed > Sanofi announces closing of Regeneron stock sale. Alternatively, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and the prospectus supplement, when available, if you request them by contacting: (1) BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at dg.prospectus_requests@bofa.com, or (2) Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com. This website uses cookies to track its audience and improve its content. Sanofi boss, Paul Hudson, said the proceeds from the sale, equating to about 20.6% of Regeneron's share capital, would finance the firm's strategy of driving innovation and growth. Sanofi expects to use the net proceeds of the offering and the repurchase to further execute on its strategy to drive innovation and growth. By continuing to browse this website, you agree to the use of such cookies. A preliminary prospectus supplement relating to the offering of Regeneron’s shares will be filed with the U.S. Securities and Exchange Commission. The public offering will occur simultaneously in the United States and internationally through underwriters led by BofA Securities and Goldman Sachs as joint book-running managers. At Sanofi's Capital Markets Day, the company announced a slew of measures intended to drive innovation and growth. PARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron … Sanofi announces closing of Regeneron stock sale Sanofi announces closing of Regeneron stock sale PARIS - May 29, 2020 – Sanofi... 04/08/2020 05:55:55 Cookie Policy +44 (0) 203 8794 460 Free Membership Login. Following completion of the proposed public offering and share repurchase, Sanofi will discontinue accounting for its ownership in Regeneron’s common shares under the equity method. When Sanofi first purchased shares of the Tarrytown, New York-based drugmaker in 2003, the stock traded below $20, compared with a closing price of $569.91 last Friday. The shares offered to the public are being offered pursuant to an existing effective shelf registration statement (including a base prospectus) that has been filed by Regeneron with the U.S. Securities and Exchange Commission (the "SEC"). This includes the previously announced overallotment option that has been fully exercised by underwriters. “Sanofi and Regeneron’s collaboration has been one of the most productive in the industry, creating significant value for both companies but more importantly, resulting in five important medicines for patients. Sanofi to Sell Its 20.6% Stake in Regeneron, but Keep Their Collaboration Intact The sale appears to be more about Sanofi's capital needs than about Regeneron's valuation. We believe the proceeds from this transaction will help further our ability to execute on our strategy to drive innovation and growth.”. Hints At Regeneron Stake Sale. Sanofi announces closing of Regeneron stock salePARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron (NASDAQ: REGN) common stock through a registered offering at a public offering price of $515.00 per share. 29 May 20 . PARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron … This includes the previously announced overallotment option that has been fully exercised by underwriters. Sanofi said Friday it would sell its shares at a price of $515 apiece. After restatement of Sanofi previously reported non-GAAP indicator (Business Net Income) and change of its definition to exclude the effect of equity method accounting for Regeneron investment, Sanofi business EPS is expected to grow by approximately +5% in 2020 at constant exchange rate compared to 2019 restated business EPS of €5.64, which is in line with Sanofi’s 2020 business EPS growth guidance. The French drugmaker holds about 23.2 million Regeneron shares, or 20.6% of the U.S. pharmaceutical company. This website uses cookies to track its audience and improve its content. 1 In connection with the offering, the underwriters will have an option to purchase up to an additional 10% of Regeneron’s shares offered, exercisable within 30 days following the pricing of the offering. On Monday, the companies announced their checkpoint inhibitor Libtayo (cemiplimab-rwlc) won Food and Drug Administration (FDA) approval for lung cancer.. Libtayo was approved for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. As previously announced, Regeneron will repurchase 9.8 million shares or $5 billion in common stock from Sanofi at the offering price less the underwriting discount. By continuing to browse this website, you agree to the use of such cookies. The public offering is occurring simultaneously in the United States and internationally through underwriters led by BofA Securities and Goldman Sachs, together with Barclays, BNP Paribas, Citigroup, J.P. Morgan, Morgan Stanley as joint book-running managers. Regeneron and Sanofi remain blinded to the ongoing portion of the Phase 3 trial and expect to report results by June. Sanofi, Regeneron chase 4th Dupixent approval with rare esophageal disease data Dupixent could score $11 billion in annual sales, according to Sanofi CEO Paul Hudson's estimates. PARIS - May 29, 2020 – Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron (NASDAQ: REGN) common stock through a registered offering at a public offering price of $515.00 per share. PARIS - May 29, 2020 - Sanofi today announced the closing of its sale of 13.0 million shares of Regeneron …